Boris P Kopnin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8665117/publications.pdf

Version: 2024-02-01

59	2,192	218381	223531
papers	citations	26 h-index	46 g-index

59	59	59	2375
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Notch signaling pathway: dual role in tumour progression and therapeutic opportunities for bladder cancer. Onkourologiya, 2019, 15, 108-116.	0.1	0
2	The influence of physical factors on recognizing blood cells in the computer microscopy systems of acute leukemia diagnosis. Journal of Physics: Conference Series, 2017, 784, 012042.	0.3	3
3	Computer microscopy in lymphoma diagnostics. Journal of Physics: Conference Series, 2017, 798, 012126.	0.3	4
4	The use of optical microscope equipped with multispectral detector to distinguish different types of acute lymphoblastic leukemia. Journal of Physics: Conference Series, 2017, 784, 012003.	0.3	2
5	Application of texture analysis methods to computer microscopy in the visible range of electromagnetic radiation. Bulletin of the Lebedev Physics Institute, 2016, 43, 306-308.	0.1	3
6	E-Cadherin repression increases amount of cancer stem cells in human A549 lung adenocarcinoma and stimulates tumor growth. Cell Cycle, 2016, 15, 1084-1092.	1.3	30
7	Tumor promotion by Î³ and suppression by Î² non-muscle actin isoforms. Oncotarget, 2015, 6, 14556-14571.	0.8	50
8	Ras-induced ROS upregulation affecting cell proliferation is connected with cell type-specific alterations of HSF1/SESN3/p21^{Cip1/WAF1}pathways. Cell Cycle, 2013, 12, 826-836.	1.3	46
9	Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene, 2012, 31, 1389-1397.	2.6	66
10	An attempt to prevent senescence: A mitochondrial approach. Biochimica Et Biophysica Acta - Bioenergetics, 2009, 1787, 437-461.	0.5	359
11	p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. Cancer Letters, 2009, 276, 143-151.	3.2	92
12	Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 3. Inhibitory effect of SkQ1 on tumor development from p53-deficient cells. Biochemistry (Moscow), 2008, 73, 1300-1316.	0.7	82
13	Repression of Sestrin Family Genes Contributes to Oncogenic Ras-Induced Reactive Oxygen Species Up-regulation and Genetic Instability. Cancer Research, 2007, 67, 4671-4678.	0.4	123
14	Genome instability and oncogenesis. Molecular Biology, 2007, 41, 329-339.	0.4	7
15	ROS up-regulation mediates Ras-induced changes of cell morphology and motility. Experimental Cell Research, 2006, 312, 2066-2073.	1.2	70
16	Activation of Ras-Ral Pathway Attenuates p53-independent DNA Damage G2 Checkpoint. Journal of Biological Chemistry, 2004, 279, 36382-36389.	1.6	16
17	Restoration of p53 tumor-suppressor activity in human tumor cells in vitro and in their xenografts in vivo by recombinant avian adenovirus CELO-p53. Gene Therapy, 2004, 11, 79-84.	2.3	24
18	Cell type-specific effects of asbestos on intracellular ROS levels, DNA oxidation and G1 cell cycle checkpoint. Oncogene, 2004, 23, 8834-8840.	2.6	34

#	Article	IF	Citations
19	The Protective Role of p53 in Ras-Induced Transformation of REF52 Cells. Molecular Biology, 2003, 37, 392-403.	0.4	5
20	Title is missing!. Molecular Biology, 2003, 37, 102-109.	0.4	3
21	Tumor Suppressor p53 and Its Homologue p73Î± Affect Cell Migration. Journal of Biological Chemistry, 2003, 278, 27362-27371.	1.6	47
22	Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene, 2002, 21, 4595-4600.	2.6	95
23	Title is missing!. Molecular Biology, 2002, 36, 522-527.	0.4	3
24	p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling. Oncogene, 2001, 20, 899-909.	2.6	62
25	p53-dependent effects of RAS oncogene on chromosome stability and cell cycle checkpoints. Oncogene, 1999, 18, 3135-3142.	2.6	40
26	Increased Karyotype Precision Using Fluorescence In Situ Hybridization and Spectral Karyotyping in Patients with Myeloid Malignancies. Cancer Genetics and Cytogenetics, 1999, 108, 166-170.	1.0	27
27	p53 DOES NOT CONTROL THE SPINDLE ASSEMBLY CELL CYCLE CHECKPOINT BUT MEDIATES G1 ARREST IN RESPONSE TO DISRUPTION OF MICROTUBULE SYSTEM. Cell Biology International, 1999, 23, 323-334.	1.4	32
28	Disruption of actin microfilaments by cytochalasin D leads to activation of p53. FEBS Letters, 1998, 430, 353-357.	1.3	75
29	Translocation (2;3)(p13;q26) in two cases of myeloid malignancies: Acute myeloblastic leukemia (M2) and blastic phase of chronic myeloid leukemia. Cancer Genetics and Cytogenetics, 1996, 87, 182-184.	1.0	11
30	Chromosome changes caused by alterations of p53 expression. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1996, 354, 129-138.	0.4	50
31	Cell-specific effects of RAS oncogene and protein kinase C agonist TPA on P-glycoprotein function. FEBS Letters, 1995, 368, 373-376.	1.3	18
32	Blast cells in child and adult AML: comparative study of morphocytochemical, immunological and cytogenetic characteristics. British Journal of Haematology, 1994, 87, 708-714.	1.2	6
33	The Cyst Wall Formation in Tillina magna (Ciliophora, Colpodidae). Archiv FÃ¼r Protistenkunde, 1994, 144, 17-29.	0.8	5
34	11q deletions in human colorectal carcinomas: Cytogenetics and restriction fragment length polymorphism analysis. Genes Chromosomes and Cancer, 1993, 6, 45-50.	1.5	59
35	Human P53, Mutated at Codon 273, Causes Distinct Effects on Nucleotide Biosynthesis Salvage Pathway Key Enzymes in Rat-1 Cells and in Their Derivatives Expressing Activated ras Oncogene. Biochemical and Biophysical Research Communications, 1993, 194, 383-390.	1.0	5
36	Genetic Events Responsible for Colorectal Tumorigenesis: Achievements and Challenges. Tumori, 1993, 79, 235-243.	0.6	8

#	Article	IF	Citations
37	Fine Structure of the Macronucleus in the Resting Cysts of the Ciliate Tillina magna. Archiv FÃ¼r Protistenkunde, 1992, 141, 27-40.	0.8	10
38	Enhanced expression of 1p32 and 1p22 fragile sites in lymphocytes in cutaneous malignant melanomas. Cancer Genetics and Cytogenetics, 1992, 58, 24-28.	1.0	11
39	Regularities of karyotypic evolution during stepwise amplification of genes determining drug resistance. Mutation Research - Reviews in Genetic Toxicology, 1992, 276, 163-177.	3.0	8
40	Newly formed chromosome-like structures in independent mouse P388 sublines with developed in vivomdr1 gene amplification. Somatic Cell and Molecular Genetics, 1991, 17, 581-590.	0.7	11
41	Karyotype pecularities of human colorectal adenocarcinomas. Human Genetics, 1991, 86, 491-6.	1.8	31
42	Two different anti-erythroid monoclonal antibodies in immunodiagnosis of human leukemias: A comparative study. International Journal of Cancer, 1989, 44, 589-592.	2.3	9
43	Cloning and characterization of DNA sequences amplified in multidrug-resistant Djungarian hamster and mouse cells. Somatic Cell and Molecular Genetics, 1987, 13, 609-619.	0.7	26
44	Chromosomes in acute nonlymphocytic leukemia. Human Genetics, 1986, 73, 137-146.	1.8	67
45	Induction of gene amplification in dzhungarian hamster cells by some chemical carcinogens. Bulletin of Experimental Biology and Medicine, 1986, 101, 845-847.	0.3	1
46	Gene amplification in Djungarian hamster cell lines possessing decreased plasma membrane permeability for colchicine and some other drugs. Chromosoma, 1985, 92, 16-24.	1.0	22
47	Regular pattern of karyotypic alterations accompanying gene amplification in Djungarian hamster cells: study of colchicine, adriablastin, and methotrexate resistance. Chromosoma, 1985, 92, 25-36.	1.0	18
48	Gene amplification in multidrug-resistant cells: Molecular and karyotypic events. BioEssays, 1985, 3, 68-71.	1.2	10
49	Genotypic and phenotypic changes determining resistance of Djungarian hamster cells to adriablastin. Bulletin of Experimental Biology and Medicine, 1983, 96, 1301-1304.	0.3	1
50	Hyperproduction of a specific protein in cells resistant to colchicine and adriablastin. Bulletin of Experimental Biology and Medicine, 1983, 96, 1304-1307.	0.3	4
51	Chromosomal rearrangements with a common breakpoint at 6p23 in five cases of myeloid leukemia. Human Genetics, 1983, 64, 254-256.	1.8	32
52	Comparison of mitostatic effect, cell uptake and tubulin-binding activity of colchicine and colcemid. Biochimica Et Biophysica Acta - General Subjects, 1981, 673, 86-92.	1.1	7
53	A mouse cell line with inherited stable colchicine resistance. Bulletin of Experimental Biology and Medicine, 1981, 91, 819-822.	0.3	1
54	Correlations between the clinical course, characteristics of blast cells, and karyotype patterns in chronic myeloid leukemia. Human Genetics, 1981, 58, 285-293.	1.8	45

#	Article	IF	Citations
55	Cytogenetic toxicity of cyclophosphamide and its metabolites in vitro. Cytogenetic and Genome Research, 1980, 26, 108-116.	0.6	70
56	Chromosomes in acute leukemia. Human Genetics, 1979, 53, 5-16.	1.8	151
57	Effect of various substances on colchicine uptake by cells sensitive and resistant to it. Bulletin of Experimental Biology and Medicine, 1979, 88, 1062-1065.	0.3	0
58	Chromosome abnormalities and clinical and morphologic manifestations of chronic myeloid leukemia. Human Genetics, 1978, 41, 143-56.	1.8	79
59	Colcemid-induced polyploidy and aneuploidy in normal and tumour cellsin vitro. International Journal of Cancer, 1975, 16, 730-737.	2.3	16